İsrail - İbranice - Ministry of Health

m.p.vet ltd - dexamethasone as sodium phosphate - תמיסה להזרקה - dexamethasone as sodium phosphate 2 mg/ml

İsrail - İbranice - Ministry of Health

padagis israel pharmaceuticals ltd, israel - clotrimazole; dexamethasone acetate; neomycin sulfate - קרם - clotrimazole 1 %; neomycin sulfate 0.645 %; dexamethasone acetate 0.044 % - combinations - combinations - treatment of dermatitis involving also a bacterial and/or fungal infection.

İsrail - İbranice - Ministry of Health

eliezer linevitz ltd. - clotrimazole; dexamethasone acetate; marbofloxacin - טיפות אוזניים - marbofloxacin 3 mg/ml; clotrimazole 10 mg/ml; dexamethasone acetate 0.9 mg/ml

İsrail - İbranice - Ministry of Health

vetmarket marketing ltd - betamethasone as valerate 0.1 %; fusidic acid as hemihydrate 0.5 % - gel - for the topical treatment of surface pyoderma in dogs such as acute moist dermatitis ("hot spots" ) and intertrigo (skin fold dermatitis) in dogs.

İsrail - İbranice - Ministry of Health

teva pharmaceutical indust.ltd - dexamethasone as sodium phosphate 1 mg/ml; neomycin as sulfate 5 mg/ml - ophthalmic solution - neomycin - steroid-responsive allergic and inflammatory disorders of the anterior segments of the eye (conjunctival, corneal, or uveal tract inflammation) or mechanical, chemical or thermal trauma where bacterial infection or a risk of bacterial ocular infection exists.

İsrail - İbranice - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

İsrail - İbranice - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

İsrail - İbranice - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

İsrail - İbranice - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

İsrail - İbranice - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.